MDACC Study No:2012-1125 ( NCT No: NCT01744691)
Title:An Open-label, Single arm, Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma with 17p Deletion
Principal Investigator:William G. Wierda
Treatment Agent:PCI-32765
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if PCI-32765 (ibrutinib)
can help to control CLL and SLL. The safety of this drug will also be studied.

Ibrutinib is designed to stop a protein from working in the cells, which may
cause the cancer cells to die or stop growing.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:PCI-32765
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Pharmacyclics, Inc.
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:William G. Wierda
For Clinical Trial Enrollment:713-792-7305
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults